Thermo Fisher

The state of the fight: 

Sanofi and GSK’s vaccine candidate demonstrated 58% efficacy against symptomatic Covid-19 in Phase 3.
  Hetero Pharma’s generic version of Merck’s molnupiravir reduced the risk of hospitalization by over 65%.
  Britain and Japan pledged a combined $514 million to CEPI’s pandemic preparedness plan.   AUTHORIZED VACCINES

 
The U.S. FDA lifted its clinical hold on Bharat Biotech’s Covaxin, clearing the way for the inactivated vaccine to…

Thermo Fisher wrapped up 2021 by buying bioscience reagents specialist PeproTech for $1.9 billion in cash, the Massachusetts-based behemoth announced last week.

The deal gives Thermo Fisher access to New Jersey-based PeproTech’s recombinant proteins portfolio, “an excellent strategic fit within our biosciences business,” per the press release.

Mentions:

The state of the fight: 

New studies supported heterologous primary regimens and heterologous boosters.
  Serum Institute of India is weighing slashing Covishield production by 50%.
  The U.S. FDA OK’d AstraZeneca’s Evusheld long-acting monoclonal antibody therapy as PrEP for certain groups.

 

AUTHORIZED VACCINES  

Mixing the AstraZeneca/Oxford or Pfizer/BioNTech vaccines with a second dose of Moderna’s shot generated non-inferior immune responses …

Thermo Fisher announced last week that it will buy North Carolina-based clinical research organization PPD for $17.4 billion in cash and approximately $3.5 billion in assumed debt.

In a boost to its pharma services business, the Massachusetts-based company will acquire PPD’s drug development platform, patient recruitment capabilities and laboratory services, the press release said.

The deal is one of several acquisitions for Thermo Fisher this year and, according to STAT, its…

Mentions:

The state of the hunt:

J&J’s vaccine became the first single-dose Covid-19 jab to receive EUL from the World Health Organization.
  A growing list of countries—including at least one COVAX AMC participant—suspended their rollouts of AstraZeneca’s vaccine over safety concerns.
  Monoclonal antibodies from Lilly and a separate mAb from GSK and Vir substantially cut the risk of hospitalization or death in people with mild or moderate Covid-19 at high risk of progression…

The state of the hunt:

COVAX has inked a deal for up to 40 million doses of Pfizer/BioNTech’s vaccine.
  India launched its mass vaccination campaign against Covid-19.
  China and India are both giving away vaccine doses to their neighbors.

 

Vaccines


Approved or authorized vaccines
 
China’s Sinovac jab more effective using three-week interval: A silver lining has emerged to last week’s middling news from the Butantan Institute’s…

Massachusetts-based Thermo Fisher announced last week its $877 million all-cash acquisition of Novasep’s Belgian viral vector manufacturing business, Henogen. The purchase will help Thermo Fisher “expand its capabilities for cell and gene vaccines and therapies globally,” the press release said.

Fellow CDMO Fujifilm Diosynth Biotechnologies also has new manufacturing muscle in the works. Fujifilm and its collaborator, the Massachusetts Center for Advanced Biological Innovation and…

Two companies last week extended a veritable frenzy of recent industry capacity enhancement announcements.

Massachusetts-based Thermo Fisher said it will expand its sterile drug development and commercial manufacturing facilities—including live virus, aseptic liquid and lyophilized vial filling capabilities—in North Carolina, the United Kingdom and Italy. The expansions are in addition to new facilities in Singapore and China the company already announced, the press release said.

The state of the hunt:

Pfizer/BioNTech’s vaccine won U.S. FDA Emergency Use Authorization.
  The inactivated vaccine from CNBG’s Beijing subsidiary secured UAE registration.
  Bharat Biotech and SII requested Indian authorization of their respective jabs.

 

Vaccines


Approved or authorized vaccines
 
The Pfizer/BioNTech vaccine extended its regulatory lead this week with new authorizations, including a U.S. nod.
 
The U.S.…

The state of the hunt:

Vaccine candidates from Novavax and J&J’s Janssen subsidiary entered Phase 3.
  Chinese regulators are reviewing inactivated vaccine candidates from CNBG for conditional authorization.
  Fujifilm’s flu drug Avigan (favipiravir) met its primary endpoint in a Phase 3 trial for treatment of Covid-19.

 

Vaccines

Phase 3 candidates:
 
China weighs approval of CNBG shots: State regulators are reviewing CNBG’s two…